BACKGROUND: The consequences of defective @entity13563 ( @entity13563 ) are not understood in sporadic @entity43 , nor have the potential role of @entity13563 proteins other than @entity5345 and @entity2674 been clearly defined. However, it is clear that defects in @entity13563 and other DNA repair pathways are important to the effectiveness of current therapies. We hypothesize that a subset of @entity43 may @entity154 in @entity13563 pathways, and that a BRCAness profile (defects in @entity13563 or other DNA repair pathways) could influence response rate and survival after treatment with @entity902 drugs. Clinical availability of a BRCAness profile in @entity1 and/or @entity5 should improve treatment outcomes. OBJECTIVE: To define the BRCAness profile of sporadic @entity43 and determine whether @entity5345 , @entity9190 , @entity24749 , @entity983 , @entity6714 , ATM, and @entity876 protein expression correlates with response to treatment, disease recurrence, and recurrence-free survival. MATERIALS AND METHODS: Protein microarray analysis of @entity43 tissue was used to determine protein expression levels for defined DNA repair proteins. Correlation with clinical and pathologic parameters in 186 @entity1 with advanced stage III-IV and grade 3 @entity43 was analyzed using Chi square, Kaplan-Meier method, Cox proportional hazard model, and cumulative incidence function. RESULTS: High @entity9190 , @entity24749 and @entity5345 expressions were significantly correlated with each other; however, elevated @entity876 expression was associated only with high @entity9190 and @entity24749 . Of all @entity1 , 9% recurred within the first year. Among early recurring @entity1 , 41% had high levels of @entity9190 , @entity24749 and @entity876 , compared to 19.5% of @entity1 without early recurrence (p=0.04). @entity1 with high levels of @entity9190 , @entity24749 and/or @entity876 had first year cumulative @entity5 incidence of 17% compared with 7% for the other groups (P=0.03). CONCLUSIONS: @entity1 with concomitantly high levels of @entity9190 , @entity24749 and @entity876 protein expression are at increased risk of early @entity43 recurrence and @entity902 resistance.

BRCAness profile of sporadic XXXX predicts disease recurrence.

@entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian carcinoma', 'sporadic ovarian carcinomas', 'ovarian cancer'] @entity154 :: ('MESH:D000013', 'Disease') :: ['harbor anomalies'] @entity13563 :: ('MESH:C535296', 'Disease') :: ['homologous recombination', 'HR'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'Women'] @entity5345 :: ('672', 'Gene') :: ['BRCA1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'tumors'] @entity2674 :: ('675', 'Gene') :: ['BRCA2'] @entity876 :: ('7157', 'Gene') :: ['P53', 'p53'] @entity983 :: ('5728', 'Gene') :: ['PTEN'] @entity9190 :: ('1302', 'Gene') :: ['PARP'] @entity24749 :: ('2177', 'Gene') :: ['FANCD2'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity6714 :: ('3014', 'Gene') :: ['H2AX']
@entity43 :: (MESH:D010051,Disease) :: ['ovarian cancer']
